BEING ALIVE: February 1995 Mark Katz, MD, and reported by Jim Stoecker
The Roche protease inhibitor, saquinavir, continues to lead the pack and is now in Phase III testing. More data on the efficacy of this drug should be available next month. Phase I studies of the Merck PI, L-524, shows reduced p24 and increased CD4 count. Abbott Laboratories are also reporting encouraging Phase I test results of its drug, ABT-538. This protease inhibitor is now moving on to Phase II/III trials. Locally, Pacific Oaks Medical Group has six ongoing studies of two different protease inhibitors. For information on these studies, call Paul Prosser at 818.906.6279.
950201
BA950205
AEGiS is made possible through unrestricted grants from Roxane Laboratories, the National Library of Medicine, and donations from users like you. Always watch for outdated information. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.
This information is designed to support, not replace, the relationship that exists between you and your doctor.